Pune, Maharashtra, October 30 2020 (Wiredrelease) Graphical Research –:According to the Graphical Research new growth forecast report titled “Middle East and Africa Bioreactors Market Size By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Product Type (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By End-user (R&D Organizations, Biopharmaceutical Manufacturers, Contract Manufacturing Organizations [CMOs]), Industry Analysis Report, Regional Outlook (South Africa, Saudi Arabia, UAE, Egypt, Qatar, Israel, Iran, Kuwait, Turkey), Application Potential, Competitive Market Share & Forecast, 2020 – 2026″, share is set to exceed USD 20.0 million by 2026.
Middle East and Africa bioreactors market is projected to progress rapidly owing to increasing number of biopharmaceutical companies in the region. Several biotechnology companies are setting up manufacturing facilities in countries such as Saudi Arabia and UAE among others. With increase in manufacturing capacities and introduction of advanced and cost-effective single-use bioreactors, the market demand will expand in the analysis timeframe.
Rising focus on research and development of vaccines and new therapeutics based on stem cells will create considerable demand for bioreactors in the region. Growing incidence of rare and chronic diseases has stimulated the need for advanced research and hence several R&D centres and emphasizing on it. For instance, in Israel, Pluristem Therapeutics, a pharmaceutical company has produced mesenchymal stem cells to treat peripheral blood disease. In addition, with increasing incidence of COVID-19, the demand for novel therapeutics has risen, that will in turn favor market expansion.
However, stringent guidelines associated with drug development process and absence of definitive standards for product approval of bioreactors could hamper the market growth in future.
Reusable bioreactors segment held over 52.0% revenue share in 2019. Reusable bioreactors are widely used for commercial purposes in mass production of biopharmaceuticals. Reusable bioreactors are mostly used for vaccine and drug production due to larger capacity scale of manufacturing. Thus, increasing prevalence of various diseases will boost adoption of therapeutics, thereby creating opportunities for bioreactors market.
Bacterial cells segment is projected to proceed at over 4.5% CAGR in the forecast timeframe. Bacterial cells are vigorous and damage resistant. Moreover, these cells provide bioreactors with high mass transfer competence, permit rapid metabolism, and supports high-cell density microbial cell cultivation and growth in the quantity of product. Such benefits will spur the segmental growth.
Monoclonal antibodies (mAb) segment held more than USD 4.0 million revenue in 2019 and is forecasted to grow robustly by 2026. Rising pervasiveness of cancer, including leukemia and breast cancer will positively impact the segment growth. Monoclonal antibodies are being rapidly used for effective cancer treatment. Furthermore, increasing research focus on mAb will offer lucrative growth potential for the segmental expansion.
Contract manufacturing organizations (CMOs) segment held around 19% revenue share in 2019. Growing concern of cost reduction will increase the preference for contract manufacturing organizations in the coming years. Also, increase in agreements for manufacture of various novel drugs will augment the adoption of bioreactors in CMOs.
UAE bioreactors market is estimated to witness 5.5% CAGR during analysis period. Increasing expenditure in pharmaceutical sector and growing number of drug manufacturing firms in the UAE will influence market growth. In addition, growing investment in research and development for biologics, stem cell production, injectables and others will positively impact the UAE bioreactors market growth.
Some of the prominent market players in Middle East and Africa bioreactors market are Cytiva, Sartorius, Merck Group and Thermo Fisher Scientific among others. These market players are undertaking strategies such as product launch and collaborations to enhance their product base in various geographical locations. For instance, in March 2018, Sartorius Stedim Biotech launched Ambr 250, a high throughput perfusion bioreactor system especially designed for optimization of therapeutic antibody production. The strategy assisted in expanding its product offerings and thus customer portfolio.
Request for a sample of this report @ https://www.graphicalresearch.com/request/1447/sample
This content has been published by Graphical Research company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at firstname.lastname@example.org.
– eTurboNews | Trends | Travel News Online